This project establishes a reproducible computational process for ligand and drug discovery, identifying multiple candidates for Nurr1, which, in the near future, can be put into practical testing grounds for validation and eventually clinical drug design.
Abstract
For a long time, Alzheimer’s disease has been among the most commonplace and fearsome neurodegenerative disorders worldwide. It is characterized by progressive cognitive decline caused by a combination of each-interacting molecular pathological processes. Despite decades of effort, therapeutic strategies targeting single mechanisms such as β-amyloid or tau pathologies have failed to achieve durable disease modification. This leads to recently increasingly relevant focus on multi-axis regulatory approaches. Nuclear receptor related 1 protein(Nurr1/NR4A2) has been under the microscope as a promising, key transcriptional regulator of neuroinflammation, neuronal survival, and even mitochondrial function. Stacking evidence shows Nurr1 inactivity to Alzheimer’s disease progression, providing grounds and necessity for this project to target it as a potential therapeutic.
In this project, a comprehensive, fully computational framework was developed to map out the ligand-binding features of Nurr1. To start off, Geometric, energetic, and machine-learning-based methods were deployed to identify, through different means, binding pockets. Then, Pharmacophore modeling and mass virtual screenings were subsequently applied to predict various candidate small molecules from trusted public chemical libraries. Next, molecular docking simulations were performed using SwissDock to eventually reveal multiple ligands with the most favorable binding energies and stable clusterings within the previously spotted cavity. Administration of the potential drug is then tested using virtual ADME and toxicity profiling, filtering down to refined candidates of drugs with optimal affinity and no significant safety concerns. At the end, this project establishes a reproducible computational process for ligand and drug discovery, identifying multiple candidates for Nurr1, which, in the near future, can be put into practical testing grounds for validation and eventually clinical drug design.
Progress in the creation and design of Multi-target directed ligands have become a promising approach in the last few years, and recent advances in medicinal chemistry and structure-based design bolster the argument for MTDLs as next-generation therapeutic candidates, notwithstanding challenges like bioavailability and...
Sumesh Kumar, Vansh Sharma, Happy et al.· Current Pharmaceutical Resea...· 0 citations
This review comprehensively summarizes and critically analyzes advances reported from 2020 to 2026 in the design, synthesis, biological evaluation, and therapeutic potential of RIV-based hybrid molecules and scaffold modifications for AD treatment.
Nitin Kumar, V. Kushwaha, Gourav Singh et al.· Bioorganic & Medicinal Chemi...· 0 citations
Three small molecules, resveratrol, curcumin, and apigenin, demonstrated strong binding affinities for NFKBIA, clarifying the priority candidate gene and feasible strategic directions, which are expected to be translated into practical pathways for precision diagnosis and treatment of AD.
Xin Li, Xue-Rong Liu, Xin-Ran Song et al.· BioMed Research Internationa...· 0 citations
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options offering only symptomatic relief. Natural fungal metabolites have recently gained attention for their neuroprotective potential. In this study, an extensive library of 18,349 fungal compounds was retrieved from the NPA...
Deepeesh Vijayan, K. Siva, Jayathraa Ramachandran et al.· Malaysian applied biology· 0 citations
Findings highlight APOE, BACE1, and CSF1R as key therapeutic targets as key therapeutic targets and identify compound 2a as a promising multi-target lead candidate for additional experimental validation in AD.
Md. Mainuddin Hossain, Towfika Rahman Singdha, Saifullah Sakib et al.· Bioinformatics and Biology I...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.